Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Matthew Harmelink MD

Matthew M. Harmelink MD

Assistant Professor, Department of Neurology, Division of Child Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin
Dr. Matthew Harmelink is an Assistant Professor with an expertise in neuromuscular medicine in the Department of Neurology, Division of Child Neurology at the Medical College of Wisconsin. He completed his Pediatric Residency at the University of Calfornia, Irvine, Child Neurology Fellowship at the Medical College of Wisconsin/Children’s Wisconsin, and Neuromuscular Medicine Fellowship at University of California, Los Angeles. Currently, he serves at the Director of the Pediatric Neuromuscular Program, Co-Director of the Neurogenetic Clinic, and Residency Director for the Child Neurology Training Program. He is currently the local PI for various neuromuscular pharmaceutical interventional trials and engages in research regarding efficacy in evaluation and treatment of pediatric neuromuscular diseases.


Dr. Harmelink has served on the advisory boards for Sarepta Inc, PTC Inc, Biogen Inc, and Avexis Inc. He is a consultant for Biogen Inc, as well as Emerging Therapy Solutions. Dr. Harmelink has infrastructure grants from MDA and PPMD and is a sub/co-I on projects funded by CureSMA. He also has an unrestricted educational grant from Sarepta. Dr. Harmelink is an unpaid board member of Three Gaits Inc.